智通财经APP讯，石药集团(01093)发布公告，集团开发的阿瑞匹坦注射液(4.4ml:32mg)(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。
该产品是新一代NK-1受体拮抗剂，是一种亚微乳注射剂，可与大脑中NK-1受体高选择性地结合并拮抗P物质，以有效预防急性和迟发性呕吐。该产品适用于预防成人术后恶心和呕吐(PONV)。与阿瑞匹坦传统剂型相比，该产品起效迅速，可显着提高患者的顺应性，并能有效降低临床使用中过敏反应的发生率，为成人术后恶心和呕吐的预防提供了更优的用药选择。
2024年9月，集团开发的阿瑞匹坦注射液(18ml:130mg)已获得药品注册批件，其主要适用于预防化疗引起的恶心呕吐。该产品的成功获批，进一步增强了集团在止吐领域的产品竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.